Upper Respiratory Infections Linked to Nonadherence to Scheduled Chemotherapy
the Cancer Therapy Advisor take:
A patient’s adherence to their chemotherapy schedule is an integral aspect to an optimal treatment outcome. A prospective cohort study led by Ahmed Taha, MD, of the Sackler Faculty of Medicine, Tel-Aviv University in Tel-Aviv, Israel, looked into the factors that led to a dose reduction, a delay in chemotherapy, or a cancellation of a patient’s planned chemotherapy.
The focus of the research was mainly delays in chemotherapy because of a mild respiratory infection during the winter. The research included 547 adult patients with solid or hematologic cancer who were undergoing chemotherapy in a cancer center during the winter of 2010 to 2011. The researchers determined that 213 of the patients followed (38.9%) experienced 306 delays in chemotherapy treatment.
The documented reasons for the delays in chemotherapy were neutropenia (84/306, 27.4%), fever or infection (73/306, 23.9%), and thrombocytopenia (26/306, 8.5%). Upper respiratory infections (OR 1.87, 95% CI 1.27–2.76), prior hospitalization, lymphopenia, and peripheral vascular disease were all found to be independent risk factors for delayed chemotherapy treatment.
Researchers conducted an adjusted analysis that analyzed nonadherence to chemotherapy only because of an infection, that analysis determined that age alone and an upper respiratory infection (OR 5.25, 95% I 2.81–9.84) were significant independent risk factors. With this knowledge, the researchers encourage clinicians to assist their patients in preventing upper respiratory infections in order to avoid delays in chemotherapy schedules.
Factors examined for dose reduction, delay in chemotherapy, or cancellation of a planned chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML